Current approaches to treatment of nonarteritic anterior ischemic optic neuropathy (NAION) rely on early retinal ganglion cell (RGC) neuroprotection. However, current neuroprotective approaches have been ineffective when administered late (>1d) after induction in rodent and primate NAION models. This is particularly problematic clinically, since nearly all patients are diagnosed at least a day post-symptom onset. We report on the success of a new neuroregenerative approach using TXA127, a pharmaceutical formulation of angiotensin (1-7) currently in Phase II for ischemic stroke.